B&C News: FDA

September 21, 2018
Keeping up with FSMA—Rules, Obligations, and Key Compliance Dates
  Wednesday, October 17, 2018 1:00 p.m. - 2:00 p.m. (EDT)  Complimentary Registration Available Online   Speakers: ■  Karin F. Baron, MSPH Senior Regulatory Consultant, Bergeson & Campbell, P.C. (B&C®) and The Acta Group (Acta®)   ■  Lynn L. Bergeson Managing Partner, B&C; President, Acta   ■  Scott J. Burya, Ph.D. Regulatory Chemist, B&C and Acta   With key implementation dates of several core elements of the U.S. Food and Drug ... read more >
December 18, 2017
Bloomberg BNA Daily Environment Report Includes Comments by Lynn L. Bergeson Regarding FDA Draft Guidance for Nanomaterial Drugs
On December 18, 2017, Lynn L. Bergeson, Managing Partner of Bergeson & Campbell, P.C. (B&C®), was quoted by the Bloomberg BNA Daily Environment Report in the article “FDA Pushes Risk-Based Approach to Nanomaterial Drugs.” Developers of drugs containing nanomaterials—substances so small they can't be seen with a regular microscope—got some advice on how to assess their risks in FDA draft guidance issued Dec. 15. […] Without having read it in detail yet, Lynn Bergeson, managing partner of Bergeson & Campbell PC, told Bloomberg BNA in a Nov. ... read more >
October 6, 2017
Inside EPA Quotes B&C Memorandum on EPA, FDA Jurisdiction for Mosquito Related Products
On October 6, 2017, Inside EPA quoted a recent Bergeson & Campbell, P.C. (B&C®) memorandum in the article “EPA wins power to oversee biotech mosquito controls.” EPA and the Food and Drug Administration (FDA) have issued new guidance clarifying that EPA has authority for regulating biotechnology (Bt) products such as genetically modified mosquitoes that are used to control the pests, a step that one industry law firm says will be helpful for navigating a federal “jurisdictional quagmire." […] In an Oct. 5 blog, the law firm Bergeson and Campbell ... read more >
June 2, 2016
Lynn L. Bergeson Presents “The Nanotechnology Legal and Regulatory Landscape” at the 2016 International Nanotoxicology Congress
On June 2, 2016, Lynn L. Bergeson, Managing Partner of Bergeson & Campbell, P.C. (B&C®), presented “The Nanotechnology Legal and Regulatory Landscape” at the 2016 International Nanotoxicology Congress in Boston. Ms. Bergeson stated that there are many ongoing global initiatives involving diverse governance aspects of nanoscale materials and many countries continue to make progress in defining nanoscale materials, addressing related definitional challenges, developing suitable governance approaches to manage potential risks, and conducting testing while developing ... read more >
April 13, 2015
Stewardship 2015 Presents Vital Program for Product Stewardship Professionals
Lynn L. Bergeson Joins Product Stewardship Society Board of Directors Stewardship 2015, June 1-3, 2015, Salt Lake City, Utah, is the only national conference dedicated to educating and equipping product stewards, industrial hygienists, environmental health and safety (EHS) professionals, and others involved in the day-to-day work of product stewardship. Stewardship 2015 is co-located with AIHce2015, the premiere conference and exposition for occupational and EHS professionals. Stewardship 2015 is presented by the Product Stewardship Society, a membership organization ... read more >
January 12, 2015
Jane Vergnes, Ph. D., Quoted in Bloomberg BNA Daily Environment Report Article "FDA Says More Data Needed to Determine If Six Chemicals Safe for Use in Sunscreens"
Comments made by Jane S. Vergnes, Ph.D., were featured in a Bloomberg BNA Daily Environment Report article covering the initial determination by the U.S. Food and Drug Administration that additional data are needed to establish that six chemicals submitted for inclusion as active ingredients in the over-the-counter sunscreen monograph using the Time and Extent Application processes are generally recognized as safe and effective.   The decisions show the bar to get new active ingredients into sunscreens remains high in the U.S., Jane Vergnes, a toxicologist working with ... read more >
June 27, 2014
Lynn L. Bergeson focus of Bloomberg BNA Daily Environment Report story "FDA Oversight May Be Required for New, Altered Chemicals, Products, Attorney Says."
Bloomberg BNA Daily Environment Report reported on Lynn L. Bergeson’s comments regarding final nanotechnology guidances released by the Food and Drug Administration. “The guidances reaffirm the FDA’s position that it has sufficient statutory authorities and policies to oversee the safety of products it regulates, Bergeson said. She expanded on that perspective in a memo her law firm issued. The FDA also restated its view that nanotechnology isn’t inherently safe or harmful, but that specific characteristics of individual products determine safety or harmfulness, ... read more >
April 6, 2012
Toxic Tort Lawsuits Seen as Less Likely in Wake of FDA Decision on Bisphenol A
The April 6, 2012, issue of Bloomberg BNA Daily Environment Report quotes Lynn L. Bergeson regarding the Food and Drug Administration’s (FDA) recent decision to reject the Natural Resources Defense Council’s petition to ban the use of bisphenol A in food ... read more >
June 27, 2011
Groups Criticize FDA Sunscreen Rules For Not Addressing Nanoscale Ingredients
The June 27, 2011, issue of BNA Daily Environment Report quotes Lynn L. Bergeson regarding the Food and Drug Administration's (FDA) response to the International Center for Technology Assessment's (ICTA) petition concerning nanoscale ingredients in ... read more >
March 24, 2011
Jayne Bultena Joins Bergeson & Campbell, P.C. and Brings Valuable Experience to Its FDA Practice
Bergeson & Campbell, P.C. (B&C), B&C Consortia Management, L.L.C. (BCCM), The Acta Group, L.L.C. (Acta), and The Acta Group EU, Ltd (Acta EU) are pleased to announce that Jayne Bultena has joined B&C as Of Counsel. Ms. Bultena brings a distinguished background on a wide range of matters arising under the Federal Food, Drug, and Cosmetic Act. She has represented Fortune 100 companies, start-ups, and venture capital investors on several issues, including developing and implementing life-cycle management strategies using patent and non-patent (Hatch-Waxman) options, including ... read more >
 < 1 2 View 10 | 25 | 50 | 100 per page
2200 Pennsylvania Avenue, NW, Suite 100W
Washington, D.C. 20037
202-557-3800 • 202-557-3836 (fax) | lawbc.com
Contact • Twitter
Privacy Policy | Terms of Use | Cookie Policy | Attorney Advertising | Trademarks
©2023 Bergeson & Campbell, P.C.
All Rights Reserved.